Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $124.18 million. The enterprise value is $101.42 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 63.36 million shares outstanding. The number of shares has increased by 3.06% in one year.
| Current Share Class | 63.36M |
| Shares Outstanding | 63.36M |
| Shares Change (YoY) | +3.06% |
| Shares Change (QoQ) | +0.70% |
| Owned by Insiders (%) | 5.91% |
| Owned by Institutions (%) | 18.72% |
| Float | 40.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.96 |
| Forward PS | n/a |
| PB Ratio | 3.97 |
| P/TBV Ratio | 3.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.76, with a Debt / Equity ratio of 0.58.
| Current Ratio | 2.76 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -121.66% and return on invested capital (ROIC) is -60.28%.
| Return on Equity (ROE) | -121.66% |
| Return on Assets (ROA) | -51.94% |
| Return on Invested Capital (ROIC) | -60.28% |
| Return on Capital Employed (ROCE) | -174.12% |
| Weighted Average Cost of Capital (WACC) | 10.57% |
| Revenue Per Employee | $247,464 |
| Profits Per Employee | -$1.46M |
| Employee Count | 56 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Pyxis Oncology has paid $1.39 million in taxes.
| Income Tax | 1.39M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +70.44% in the last 52 weeks. The beta is 1.43, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | +70.44% |
| 50-Day Moving Average | 1.78 |
| 200-Day Moving Average | 2.25 |
| Relative Strength Index (RSI) | 48.45 |
| Average Volume (20 Days) | 688,416 |
Short Selling Information
The latest short interest is 1.99 million, so 3.14% of the outstanding shares have been sold short.
| Short Interest | 1.99M |
| Short Previous Month | 2.27M |
| Short % of Shares Out | 3.14% |
| Short % of Float | 4.88% |
| Short Ratio (days to cover) | 5.33 |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of $13.86 million and -$81.74 million in losses. Loss per share was -$1.30.
| Revenue | 13.86M |
| Gross Profit | 11.47M |
| Operating Income | -83.18M |
| Pretax Income | -80.35M |
| Net Income | -81.74M |
| EBITDA | -78.09M |
| EBIT | -83.18M |
| Loss Per Share | -$1.30 |
Full Income StatementBalance Sheet
The company has $41.02 million in cash and $18.26 million in debt, with a net cash position of $22.76 million or $0.36 per share.
| Cash & Cash Equivalents | 41.02M |
| Total Debt | 18.26M |
| Net Cash | 22.76M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 31.27M |
| Book Value Per Share | 0.49 |
| Working Capital | 29.04M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5.09M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 82.77% |
| Operating Margin | -600.19% |
| Pretax Margin | -579.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.06% |
| Shareholder Yield | n/a |
| Earnings Yield | -65.82% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Pyxis Oncology is $6.89, which is 251.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.89 |
| Price Target Difference | 251.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 61.06% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pyxis Oncology has an Altman Z-Score of -11.51. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.51 |
| Piotroski F-Score | n/a |
